ArticleContemporary oncology (Poznan, Poland)2013
The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression.
Article in Contemporary oncology (Poznan, Poland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Preoperative plasma fibrinogen is associated with poor prognosis in esophageal carcinoma: a meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Pooled it
- Pooled it
- Structure-functionality relationship of collagen-fibrin interpenetrating hydrogels for engineered tumor-stroma models.Acta biomaterialia · 2026Article
- A novel clinical FIT model predicts prognosis of unresectable hepatocellular carcinoma treated with TACE combined with lenvatinib and PD-1 inhibitors therapy.Frontiers in immunology · 2026Article
- Preoperative blood neutrophil-to-lymphocyte ratio, hematocrit and fibrinogen predict prognosis in colorectal cancer.Biomarkers in medicine · 2025Article
- A new risk algorithm combining D-dimer and HE4 differentiates borderline tumor from patients with ovarian tumor.Translational cancer research · 2025Article
- Development and validation of the FAAP model for prognostic stratification in HCC patients treated with TACE, sintilimab plus bevacizumab: a multicenter study.Frontiers in immunology · 2025Article
- Phase I Trial of Upamostat Combined With Gemcitabine in Locally Unresectable or Metastatic Pancreatic Cancer: Safety and Preliminary Efficacy Assessment.Cancer medicine · 2025Article
- Transcriptomic Meta-Analysis Identifies Upregulated Clotting and Fibrinolysis Pathways in Colorectal Cancer Tumors Containing Hereditary PMS2 Mismatch Repair Deficiency.microPublication biology · 2024Article
- Article
- Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment.Oncology letters · 2023Article
- Physical, Mechanical, and Biological Properties of Fibrin Scaffolds for Cartilage Repair.International journal of molecular sciences · 2022Review
- Review
- Article
- Machine learning to predict the cancer-specific mortality of patients with primary non-metastatic invasive breast cancer.Surgery today · 2021Article
- Elevated Pretreatment Fibrinogen-to-Lymphocyte Percentage Ratio Predict Tumor Staging and Poor Survival in Non-Small Cell Lung Cancer Patients with Chemotherapy or Surgery Combined with Chemotherapy.Cancer management and research · 2021Article
- Alphastatin-C a new inhibitor of endothelial cell activation is a pro-arteriogenic agentOncotarget · 2020Article
- Article
- Low Albumin to Fibrinogen Ratio Predicts Poor Overall Survival in Esophageal Small Cell Carcinoma Patients: A Retrospective Study.Cancer management and research · 2020Article
- Acquired von Willebrand Syndrome Associated with Cardiovascular Diseases.Journal of atherosclerosis and thrombosis · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Participation of fibrin, fibrinogen, and their degradation products in pathogenesis and progression of cancer may lead to complications of thromboembolic events. The tumor may be a source of fibrinogen. Fibrinogen inside the tumor is one of the factors of its growth and metastasis. Fibrinogen, fibrin and their degradation products possess proinflammatory activity. They indirectly stimulate endothelium to secrete von Willebrand factor, leading to activation of platelets accompanying neoplastic disorders. Fragments E and D are the end products of fibrin(ogen) degradation and E and DD are the end products of stabilized fibrin. E stimulates proliferation, migration and differentiation of endothelial cells, contributing to tumor vasculature. Increased levels of DD are observed in malignant neoplasms, such as breast, lung, colon and ovary cancers. In breast cancers DD correlates with progression of disease and metastasis. The role of fibrinogen and the products of its degradation in the progression of various tumors is not sufficiently understood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.